Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China.
School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, China.
ACS Appl Mater Interfaces. 2020 Apr 1;12(13):14839-14854. doi: 10.1021/acsami.9b22781. Epub 2020 Mar 20.
A safe and efficient delivery system is critical for clinical application of siRNA. However, the conventional electrostatic interaction-based siRNA nanoplexes with bulk mixing preparation were always unsatisfactory for its stability and safety. In this study, the new core-shell lipid/PCL-PEI/siRNA nanoparticles (LPS NPs) endowing holonomic constraint of siRNA in the inner core were prepared by microfluidic technology. On the microfluidic chip, siRNAs were completely compressed into the inner hydrophilic core of reverse PCL-PEI micelles at a low N/P ratio of 5, followed by coating a neutral lipid membrane to form core-shell nanoparticles, which had a uniform size (120.2 ± 1.4 nm) and a negative charge (-8.8 ± 1.6 mV). Compared to bulk mixing-based LMS NPs, the lower usage of cationic PCL-PEI materials and stronger protection of siRNA in serum were found in the microfluidic-based LPS NPs. Furthermore, it was demonstrated that the LPS NPs exhibited significant downregulation of EGFR mRNA and protein expression level both in vitro and in vivo, and showed significant inhibition of tumor growth following systemic administration along with no obvious systemic toxicity. These findings demonstrated that the microfluidic-based lipid/polymer hybrid nanoassemblies would offer a promising siRNA delivery system for clinical application.
安全有效的递送系统对于 siRNA 的临床应用至关重要。然而,传统的基于静电相互作用的 siRNA 纳米复合物通过批量混合制备,其稳定性和安全性始终不尽人意。在本研究中,通过微流控技术制备了具有完整约束 siRNA 在内核内的新型核壳脂质/PCL-PEI/siRNA 纳米颗粒(LPS NPs)。在微流控芯片上,siRNA 在低 N/P 比为 5 的情况下完全被压缩到反向 PCL-PEI 胶束的亲水性内核中,然后包覆中性脂质膜形成核壳纳米颗粒,其粒径均匀(120.2±1.4nm),带负电荷(-8.8±1.6mV)。与基于批量混合的 LMS NPs 相比,在 LPS NPs 中发现了阳离子 PCL-PEI 材料的用量更低,并且在血清中对 siRNA 的保护更强。此外,研究表明,LPS NPs 在体外和体内均显著下调了 EGFR mRNA 和蛋白的表达水平,并在全身给药后显著抑制了肿瘤生长,同时没有明显的全身毒性。这些发现表明,基于微流控的脂质/聚合物杂化纳米组装体将为临床应用提供一种有前途的 siRNA 递送系统。